https://www.renatustx.com/news/renatus-unveils-next-generation-single-isomer-cyclodextrins%3A-a-breakthrough-beyond-hp%CE%B2cd 2025-11-21 https://www.renatustx.com/news/renatus-selected-for-the-national-research-project-funded-by-kor 2025-03-21 https://www.renatustx.com/news/renatus-presented-preclinical-data-on-its-cholesterol-modulator-for-alzheimer%E2%80%99s-disease 2025-02-08 https://www.renatustx.com/news/renatus-was-selected-for-the-merck's-2024-advance-biotech-grant-program-korea 2024-10-21 https://www.renatustx.com/news/renatus-has-been-granted-a-us-patent-for-chronic-kidney-disease-treatment-using-its-proprietary-cholesterol-metabolism-modulator 2024-03-20 https://www.renatustx.com/news/renatus-was-introduced-on-pax-economy-tv 2023-12-26 https://www.renatustx.com/news/renatus-presented-data-on-rn-005%2C-a-cholesterol-modulator%2C-in-preclinical-chronic-kidney-disease-models-at-the-2023-scale-up-challenge-lab-conference 2024-07-31 https://www.renatustx.com/news/renatus-was-slected-for-the-scale-up-challenge-lab-program 2023-11-22 https://www.renatustx.com/news/renatus%2C-carbohyde-sign-mou-to-co-develop-novel-cholesterol-modulators-for-cns-disease-applications 2023-11-22 https://www.renatustx.com/news/renatus-has-been-granted-a-key-patent-for-novel-cyclodextrins 2023-11-22 https://www.renatustx.com/news/renatus-was-selected-for-the-hospital-based-business-innovation-center-(hbic)-program 2023-11-22 https://www.renatustx.com/news/renatus-was-selected-for-the-startup-focused-university-program 2023-11-22 https://www.renatustx.com/news/renatus-was-selected-for-the-smart-x-bio-program 2023-11-22 https://www.renatustx.com/news/renatus-was-selected-for-the-hospital-based-business-innovation-center-(hbic)-program 2023-11-22 https://www.renatustx.com/news/renatus-launches-its-official-website 2024-03-20